Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 1.00 |
| ▸ | EGFR | P00533 | 8/20 | 1.00 |
| ▸ | ITK | Q08881 | 5/20 | 0.81 |
| ▸ | LCK | P06239 | 5/20 | 0.81 |
| ▸ | TEC | P42680 | 4/20 | 0.81 |
| ▸ | BMX | P51813 | 4/20 | 0.81 |
| ▸ | LYN | P07948 | 4/20 | 0.81 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.81 |
| ▸ | TXK | P42681 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.81 |
| ▸ | FYN | P06241 | 2/20 | 0.81 |
| ▸ | YES1 | P07947 | 2/20 | 0.81 |
| ▸ | HCK | P08631 | 2/20 | 0.81 |
| ▸ | FGR | P09769 | 2/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | FER | P16591 | 2/20 | 0.81 |
| ▸ | CSK | P41240 | 2/20 | 0.81 |
| ▸ | BLK | P51451 | 2/20 | 0.81 |
| ▸ | JAK3 | P52333 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200391 | 0.95 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL201548 | 0.95 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL200392 | 0.95 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL18335275 | 0.91 | BTK (0.86) | BTKEGFRITKLCKTEC | |
| SCHEMBL20144255 | 0.91 | BTK (0.91) | BTKEGFRITKLCKTEC | |
| SCHEMBL22777861 | 0.90 | BTK (0.82) | BTKEGFRITKLCKTEC | |
| SCHEMBL20144259 | 0.90 | BTK (0.83) | BTKEGFRITKLCKTEC | |
| Ibrutinib SCHEMBL2244865 | 0.90 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| Ibrutinib SCHEMBL201641 | 0.90 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| Ibrutinib SCHEMBL2244870 | 0.90 | BTK (1.00) | BTKEGFRITKLCKTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007611-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2017-01-12 | — | — | US | claimed |
| US-8952015-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20140171453-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-06-19 | — | — | US | claimed |
| US-20140135347-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-05-15 | — | — | US | claimed |
| EP-2529622-A1 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-12-05 | — | — | EP | claimed |
| US-20120277254-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-01 | — | — | US | claimed |
| US-20120252821-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-10-04 | — | — | US | claimed |
| US-20120252822-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-10-04 | — | — | US | claimed |
| EP-2201840-B1 | Inhibitors of Bruton's Tyrosine Kinase | PHARMACYCLICS INC (US) | 2011-11-02 | — | — | EP | claimed |
| US-8008309-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2011-08-30 | — | — | US | claimed |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-02-18 | — | — | US | claimed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | claimed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| EP-2081435-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | claimed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | claimed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | claimed |
| WO-2008039218-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20140171453-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20170007611-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20120277254-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20120252822-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20120252821-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 728/4885ITK 128/4885 |
| US-20140135347-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885ITK 135/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | BTK 1/4885EGFR 703/4885ITK 72/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | BTK 1/4885EGFR 1536/4885ITK 100/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | BTK 1/4885EGFR 1550/4885ITK 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.